Open AccessAssessment of geographic access to monoclonal antibodies in the United States
Author(s) -
Benjamin Rader,
Christopher Whaley,
Wesley Rogers,
Professor John S Brownstein,
Jonathan Cantor
Publication year - 2022
Publication title -
journal of travel medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.985
H-Index - 59
eISSN - 1708-8305
pISSN - 1195-1982
DOI - 10.1093/jtm/taac018
Subject(s) - medicine , covid-19 , monoclonal antibody , vaccination , virology , antibody , immunology , outbreak , infectious disease (medical specialty) , disease
Using spatial modeling techniques, we highlight disparities in access to monoclonal antibodies (mAbs) used to treat COVID-19 patients. Fifteen million individuals in the United States must travel over 30 min to access mAbs. Areas with lower COVID-19 vaccination rates have worse access to essential COVID-19 therapeutics.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom